Stuart Poulton, EVP, Chief Development Officer at Karyopharm Therapeutics Inc. (KPTI), sold 378 shares at $8.63 ($3K) on 2026-02-17, disclosed to the SEC on 2026-02-19.
Seasonal sale ($3k) by EVP, Chief Development Officer — this insider has traded KPTI in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| Filing → |
| KPTI | SELL | 2026-03-03 | $48K | — | Filing → |
| KPTI | SELL | 2025-09-16 | $3K | — | Filing → |
| KPTI | SELL | 2025-07-30 | $835 | — | Filing → |